ENTRY INHIBITOR/CCR5 ANTAGONIST
Selzentry is a prescription drug approved by the Food and Drug Administration (FDA) to treat adults with CCR5-tropic HIV-1 in combination with other antiretroviral medications. Selzentry is also referred to by its drug name, Maraviroc, and by the abbreviation MVC.
Selzentry is an antiviral medication of the class known as entry inhibitors or CCR5 antagonists. Selzentry is believed to work by preventing HIV from replicating in cells.
How do I take it?
Prescribing information states that Selzentry is taken twice daily.
Selzentry comes in tablet form.
The FDA-approved label for Selzentry lists common side effects including cold symptoms, fever, rash, cough, and dizziness.
Rare but serious side effects listed for Selzentry include severe hypersensitivity reactions and liver, heart, and kidney problems.
For more details about this treatment, visit:
Overview of HIV Treatments – AIDS.gov